Muteins of epidermal growth factor exhibiting enhanced binding at low pH
AssigneeChiron Corporation
InventorsGuy T. Mullenbach, Jeffrey M. Blaney, Steven Rosenberg
Life of this patent
Estimating the term…
Abstract
EGF muteins in which the histidine at position 16 is replaced with a neutral or acidic amino acid exhibit activity at pHs lower than obtainable with wild type EGF.
Claims5
An EGF mutein, said EGF mutein selected from the group consisting of:
- (a) φEGF-Q12;
- (b) φEGF-W13;
- (c) EGF-Q12;
- and
- (d) EGF-W13.
A pharmaceutical composition, said pharmaceutical composition comprising an EGF mutein, said EGF mutein selected from the group consisting of:
- (a) φEGF-Q12;
- (b) φEGF-W13;
- (c) EGF-Q12;
- and
- (d) EGF-W13
- and a pharmaceutically acceptable carrier.
A polynucleotide, said polynucleotide encoding an EGF mutein, said EGF mutein selected from the group consisting of:
- (a) φEGF-Q12;
- (b) φEGF-W13;
- (c) EGF-Q12;
- and
- (d) EGF-W13.
A method of treating a condition selected from the group consisting of gastric ulcer, duodenal ulcer, and gastric hyperacidity, said method comprising the step of administering an effective amount of an EGF mutein, said EGF mutein selected from the group consisting of:
- (a) φEGF-Q12;
- (b) φEGF-W13;
- (c) EGF-Q12;
- and
- (d) EGF-W13
- to a patient in need of treatment for said condition.
A method of treating injury or trauma to the dermis, epidermis or cornea, said method comprising the step of administering an effective amount of an EGF mutein, said EGF mutein selected from the group consisting of:
- (a) φEGF-Q12;
- (b) φEGF-W13;
- (c) EGF-Q12;
- and
- (d) EGF-W13
- to a patient in need of treatment for injury or trauma to the dermis, epidermis or cornea.
Dependencies are inferred from the claim text.